Source: https://www.bankofengland.co.uk/-/media/boe/files/prudential-regulation/policy-statement/2026/january/ps126app1.pdf · captured 2026-09-29 · checked 2026-09-29 · c75b8196

Page 407 thumbnail
21639 This document is effective from 1 January 2027 to accompany PS1/26.
21640Please see: www.bankofengland.co.uk/prudential-regulation/publication/2026/january/implementation-of-basel-3-1-final-rules-policy-statement.
21641 PRA2026/1
21643 5.13 A firm must ensure that:
21644 (1) its exposure models used for calculating regulatory CVA are part of a CVA risk
21645 management framework that includes the identification, measurement, management,
21646 approval and internal reporting of CVA risk;
21648 (2) its senior management is actively involved in the risk control process and must regard
21649 CVA risk control as an essential aspect of the business to which sufficient resources are
21650 devoted;
21652 (3) it has a process for ensuring compliance with a documented set of internal policies,
21653 controls and procedures concerning the operation of the exposure system it uses for
21654 calculating CVA under the firm’s applicable accounting framework;
21656 (4) it maintains an independent control unit that is responsible for the effective initial and
21657 ongoing validation of its exposure models, which is:
21659 (a) independent from the business credit and trading units, including the CVA desk;
21661 (b) adequately staffed; and
21663 (c) reports directly to senior management of the firm;
21665 (5) its documentation of the process for initial and ongoing validation of its exposure models:
21667 (a) is detailed enough to enable a third party to understand how the models operate, their
21668 limitations, and their key assumptions, and to recreate the analysis;
21670 (b) sets out the minimum frequency with which ongoing validation will be conducted as
21671 well as other circumstances under which additional validation will be conducted; and
21673 (c) describes how the validation is conducted with respect to data flows and portfolios,
21674 what analyses are used and how representative counterparty portfolios are
21675 constructed;
21677 (6) the pricing models used to calculate exposure for a given path of risk factors must:
21679 (a) be tested against appropriate independent benchmarks for a wide range of market
21680 states as part of the initial and ongoing model validation process; and
21682 (b) for options, account for the non-linearity of option value with respect to risk factors;
21684 (7) its internal audit function carries out an independent review of the overall CVA risk
21685 management process on a regular basis, covering both the activities of the CVA desk and
21686 the independent risk control unit;
21688 (8) it defines criteria against which to assess the exposure models and their inputs, and has a
21689 written policy describing the process to assess performance of the exposure models and
21690 remedy unacceptable performance;
21692 (9) its exposure models capture transaction-specific information in order to aggregate
21693 exposures at the level of the netting set;
21695 (10) it assigns transactions to the appropriate netting set within the model;
21697 (11) it reflects transaction terms and specifications in its exposure models in a timely, complete
21698 and conservative fashion;
21700 Page 407 of 492